When Cutaneous Lupus Resists Treatment, Could Litifilimab Help?

In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses investigational litifilimab and its potential role in treating cutaneous lupus erythematosus (CLE).

Werth explains that patients whose disease remains active despite antimalarial treatment often receive immunosuppressants, including methotrexate or mycophenolate mofetil. However, these therapies do not consistently control symptoms, leaving patients with refractory disease in need of additional options.

The discussion explores the 52-week AMETHYST findings, including clear or almost clear skin in approximately 27% of participants who received litifilimab from the start. Werth emphasizes that complete clearance is not necessary for meaningful benefit. Reduced redness, scaling, and lesion burden can improve quality of life even when patients do not meet that endpoint.

Speed of response is another consideration. Werth notes that hydroxychloroquine can take at least 2 months to begin working. During that interval, uncontrolled disease, particularly discoid lupus, can lead to scarring, permanent hair loss, and pigmentary changes. Although the findings do not establish that litifilimab prevents permanent damage, she explains why earlier disease control matters.

Werth also addresses the study design, distinguishing the initial placebo-controlled period from the subsequent